Akyar · BMC primary care 2026 · retrospective case-control study · n=1324

Systemic immune-inflammation index: a novel tool for hypertension management in primary care.

Cited 1 times in the scientific literature.

Level 4 - case-series / case-control

Retrospective case-control study

PubMed 41840494 · doi:10.1186/s12875-026-03276-8 · record verified 2026-08-28

What was done

A retrospective case-control study evaluated 655 hypertensive patients and 669 healthy controls aged 18 years or older. Individuals with acute or chronic infections, malignancy, autoimmune, or rheumatologic diseases were excluded. The systemic immune-inflammation index (SII) was calculated from routine complete blood counts (platelet × neutrophil / lymphocyte). Group differences, diagnostic accuracy, and associations were evaluated using the Mann-Whitney U test, receiver operating characteristic (ROC) curve analysis, and multivariate logistic regression.

What was found

Median SII was significantly higher in hypertensive patients compared with healthy controls (536.9 vs. 381.3, p < 0.0001). ROC analysis identified an optimal SII cut-off value of 520.45 for identifying hypertension (AUC = 0.73, 95% CI: 0.70-0.76), with 52.4% sensitivity and 83.6% specificity. Individuals with SII > 520.45 had 7.3-fold higher odds of hypertension compared to the reference group with SII <= 520.45 (OR = 0.137, B = -1.986, 95% CI: 0.099-0.191, p < 0.0001). SII levels were significantly higher in newly diagnosed hypertensive patients compared with previously diagnosed patients (p < 0.001). There was no significant difference in SII values between hypertensive patients with and without comorbidities (p = 0.596).

Why it matters

The study demonstrates that SII, a low-cost marker calculated from routine complete blood counts, is elevated in hypertension and may provide adjunctive value for risk stratification in primary care.

Limits

The retrospective case-control design precludes causal inference. Sensitivity was low at 52.4%, limiting utility as a standalone screening tool. The abstract does not report antihypertensive medications, lifestyle confounders, or longitudinal follow-up.

Cited by